INS and cancer: However, exploring the effectiveness of combining therapies that potentially enhance insulin sensitivity, such as GLP‐1 agonists, GLT2 inhibitors, and exercise measures, with standard cancer treatments to improve response in specific patient groups is a promising area for future research.